Antibodies against human CSF-1R
The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
1. An antibody that binds to human CSF-1R, characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2, and a CDR1 region of SEQ ID NO:3, and the light chain variable domain comprises a CDR3 region of SEQ ID NO 4, a CDR2 region of SEQ ID NO:5, and a CDR1 region of SEQ ID NO:6, or a CDR grafted, humanized, or T cell epitope depleted antibody variant thereof.
2. The antibody according to claim 1 , characterized in comprising the amino acid sequence of the heavy chain variable domain is SEQ ID NO: 7, and the amino acid sequence of the light chain variable domain is SEQ ID NO:8, or a CDR grafted, humanized, or T cell epitope depleted antibody variant thereof.
3. The antibody according to claim 1 , characterized in binding to same epitope as the deposited antibody DSM ACC2922.
4. The antibody according to claim 1 , wherein said antibody is an antibody fragment that binds to human CSF-1R.
5. The antibody according to claim 1 , characterized in that said antibody is of human IgG4 subclass or is of human IgG1 subclass.
6. The antibody according to claim 1 , wherein the antibody is a monoclonal, chimeric, single chain, or multispecific antibody.
7. An immunoconjugate comprising the antibody according to claim 1 and a cytotoxic agent.
8. The immunoconjugate according to claim 7 , wherein the cytotoxic agent is a chemotherapeutic agent, a growth inhibitory agent, a toxin, or a radioactive isotope.
9. A pharmaceutical composition characterized in comprising an antibody according to claim 1 .
10. The pharmaceutical composition according to claim 9 , further comprising a pharmaceutically acceptable carrier.
11. The antibody according to claim 1 for the treatment of cancer.
12. The antibody according claim 1 for the treatment of bone loss.
13. The antibody according to claim 1 for the prevention or treatment of metastasis.
14. The antibody according to claim 1 for the treatment of inflammatory diseases.
15. An antibody, or antibody fragment thereof, that binds to human CSF-1R, obtained from or produced by hybridoma cell line <CSF-1R>7H5.2G10.